Enquirer Consulting Group

Reachable Buyer Map

Prepared for Dr. Tia Lyles-Williams · HelaPlex · August 2026
What you have built has two buyers at opposite ends of the same industry. One is a founder who needs bench space and a first run. The other is a technical operations leader at a company that already owns a molecule and needs somebody to make it. They are reached in completely different ways, and almost nobody works both. This page is the market side of that: the segments, who signs inside each one, and roughly how many companies sit there. It describes the market rather than your business, and there is nothing to buy at the end of it.
Clinical and preclinical biotech companies
The core outsourced manufacturing buyer and the largest group on this page. Small teams, no plant of their own, and a program that has to move from the bench into a real process before the next raise. The decision is made by three or four people and it is made once per program.
Who signs: VP of CMC, head of technical operations, head of process development, chief scientific officer. At companies under fifty people, the CEO.
5,000 to 5,800
US employers registered in biotechnology research and development, of which roughly 1,300 carry 20 or more people on the plan
Pharmaceutical and biologics producers
Companies that already run their own plants and still buy outside capacity, usually for a second product, a tight timeline or a process their own site was never built for. Slower to open and far stickier once open, because the qualification work is expensive enough that nobody wants to repeat it.
Who signs: VP of manufacturing, site head, head of external manufacturing, supply chain director, and the sourcing lead who owns outsourced services.
2,400 to 2,900
US employers across pharmaceutical and medicine production; roughly 1,100 at 20 or more
Cell, gene and advanced therapy developers
The segment where the register understates the market badly. A company developing a cell therapy files as research, not as production, so the countable manufacturing layer below is a fraction of the real developer population. That gap is the whole reason this group is hard to buy a list for and open to anyone who builds one.
Who signs: head of CMC, VP of process development, quality lead, and the founder at the earliest stage.
Roughly 800 to 1,000 registered as producers
the countable biological product production layer only; the developer layer above it files as research and is not separately enumerated
Diagnostics and in vitro companies
Adjacent rather than central, and worth naming because the buying group looks almost identical. Same quality vocabulary, same regulatory clock, same need for somebody who has sat through an inspection before. Shorter cycles than therapeutics and a lower bar to a first conversation.
Who signs: VP of operations, director of quality and regulatory, head of manufacturing, and the CEO at emerging companies.
400 to 600
US employers registered in in vitro diagnostic substance production
University and health system spinouts
Your other buyer, and a genuinely different market. The company often does not exist yet, so it cannot be found in any register of companies. It is found through the office that licenses the science and the faculty founder behind it, both of which are nameable a year before there is anything to sell to.
Who signs: director of technology transfer, licensing manager, incubator or accelerator director, the faculty founder, and the first hire who is a real operator.
Roughly 190 to 220 institutions
US research universities running a technology transfer office; the spinouts themselves are not enumerated anywhere public until they incorporate
The Greater Philadelphia cluster
Your home market, and the one where a room and a plant in the same region is an argument nobody else in the country can make to the same company. Small enough to work by name from end to end, which is unusual, and which is exactly why it should not be left to whoever happens to walk in.
Who signs: founder or CEO, site head, head of operations, and on the workforce side the economic development lead and the training director.
1,100 to 1,400
life science employers across the Philadelphia region, counting research, production and diagnostics together

Where the openings are

1
Your two buyers are never in the same room. The founder looking for bench space is at a demo day or a university office. The technical operations leader choosing where a program gets made is at a conference you have to pay to stand at, and is not looking for a workspace. One channel keeps returning to whichever of those two doors it already knows. Two named audiences is a different reach problem, and a solvable one.
2
This is bought at a moment, not on a cycle. A financing round closes, a program moves out of research, a partner site drops a slot, a CMC lead is hired. Those moments are visible from outside if somebody is watching several thousand companies for them, and invisible if you are waiting for the right person to remember your name. Watching a whole segment for a trigger is mechanical work, and it is the part a referral network cannot do.
3
The advanced therapy segment is the one lists under-work. Because developers file as research rather than production, anyone buying a ready made list of biologics manufacturers reaches the plants and misses the companies that need one. Working that segment properly takes identification rather than purchase, which is why it stays open, and why a first conversation there is far less crowded.
Built from public registries, counts banded deliberately. Company counts cover US employers that file a benefit plan, so owner-only and very small companies are not published and the real population is larger. Industry codes are self-reported by the companies themselves, and the Philadelphia figure counts the region rather than the city.
ENQUIRER CONSULTING GROUP
enquirerconsulting.com